User login
Key clinical point: Patients with rheumatoid arthritis (RA) currently using low-dose oral glucocorticoid (7.5 mg or lower of prednisolone equivalent dose/day) were at a 59% increased risk of sustaining clinical vertebral fracture compared with past users.
Major finding: Although the overall risk for osteoporotic fractures was not different between past and current users of low-dose oral glucocorticoids (adjusted hazard ratio [aHR], 1.14; 95% confidence interval [CI], 0.98-1.33), the risk for clinical vertebral fracture was significantly higher with current use (aHR, 1.59; 95% CI, 1.11-2.29).
Study details: This was a retrospective cohort study of 15,123 adults aged 50 years or older from the Clinical Practice Research Datalink who were diagnosed with RA between 1997 and 2017.
Disclosures: No specific funding was received for this study. AM Burden and JP van den Bergh reported receiving grants and lectures/advisory board meetings fees from various sources. FD Vries supervised 3 PhD students who were employed with F. Hoffmann La Roche Ltd. All the other authors declared no conflict of interests.
Source: Abtahi S et al. Rheumatology (Oxford). 2021 Jul 13. doi: 10.1093/rheumatology/keab548.
Key clinical point: Patients with rheumatoid arthritis (RA) currently using low-dose oral glucocorticoid (7.5 mg or lower of prednisolone equivalent dose/day) were at a 59% increased risk of sustaining clinical vertebral fracture compared with past users.
Major finding: Although the overall risk for osteoporotic fractures was not different between past and current users of low-dose oral glucocorticoids (adjusted hazard ratio [aHR], 1.14; 95% confidence interval [CI], 0.98-1.33), the risk for clinical vertebral fracture was significantly higher with current use (aHR, 1.59; 95% CI, 1.11-2.29).
Study details: This was a retrospective cohort study of 15,123 adults aged 50 years or older from the Clinical Practice Research Datalink who were diagnosed with RA between 1997 and 2017.
Disclosures: No specific funding was received for this study. AM Burden and JP van den Bergh reported receiving grants and lectures/advisory board meetings fees from various sources. FD Vries supervised 3 PhD students who were employed with F. Hoffmann La Roche Ltd. All the other authors declared no conflict of interests.
Source: Abtahi S et al. Rheumatology (Oxford). 2021 Jul 13. doi: 10.1093/rheumatology/keab548.
Key clinical point: Patients with rheumatoid arthritis (RA) currently using low-dose oral glucocorticoid (7.5 mg or lower of prednisolone equivalent dose/day) were at a 59% increased risk of sustaining clinical vertebral fracture compared with past users.
Major finding: Although the overall risk for osteoporotic fractures was not different between past and current users of low-dose oral glucocorticoids (adjusted hazard ratio [aHR], 1.14; 95% confidence interval [CI], 0.98-1.33), the risk for clinical vertebral fracture was significantly higher with current use (aHR, 1.59; 95% CI, 1.11-2.29).
Study details: This was a retrospective cohort study of 15,123 adults aged 50 years or older from the Clinical Practice Research Datalink who were diagnosed with RA between 1997 and 2017.
Disclosures: No specific funding was received for this study. AM Burden and JP van den Bergh reported receiving grants and lectures/advisory board meetings fees from various sources. FD Vries supervised 3 PhD students who were employed with F. Hoffmann La Roche Ltd. All the other authors declared no conflict of interests.
Source: Abtahi S et al. Rheumatology (Oxford). 2021 Jul 13. doi: 10.1093/rheumatology/keab548.